KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Shares Outstanding (2016 - 2026)

Regeneron Pharmaceuticals has reported Shares Outstanding over the past 18 years, most recently at $1.8 million for Q1 2026.

  • For Q1 2026, Shares Outstanding changed 0.0% year-over-year to $1.8 million; the TTM value through Mar 2026 reached $1.8 million, changed 0.0%, while the annual FY2025 figure was $1.8 million, 98.68% down from the prior year.
  • Shares Outstanding for Q1 2026 was $1.8 million at Regeneron Pharmaceuticals, roughly flat from $1.8 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $136.1 million in Q1 2025 and troughed at $1.8 million in Q2 2022.
  • A 5-year average of $40.3 million and a median of $1.8 million in 2022 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 7416.67% in 2024 and later tumbled 98.68% in 2025.
  • Year by year, Shares Outstanding stood at $1.8 million in 2022, then soared by 7294.44% to $133.1 million in 2023, then rose by 2.18% to $136.0 million in 2024, then tumbled by 98.68% to $1.8 million in 2025, then changed by 0.0% to $1.8 million in 2026.
  • Business Quant data shows Shares Outstanding for REGN at $1.8 million in Q1 2026, $1.8 million in Q4 2025, and $136.2 million in Q3 2025.